IgA-Enriched MASLD Subtype and the Gut–Liver Axis
Researchers identified an IgA-enriched subgroup of MASLD associated with increased liver-related events. Spatial transcriptomics and tissue analyses further revealed IgA-expressing B-lineage cells in portal liver regions, highlighting coordinated immune activity along the gut–liver axis.
Image Credit: Kimura, Wakabayashi, et.al. Journal of Hepatology
Scientific Frontline: Extended "At a Glance" Summary: High-IgA MASLD Subtype
The Core Concept: A specific subtype of metabolic dysfunction-associated steatotic liver disease (MASLD) characterized by enriched Immunoglobulin A (IgA) levels and an increased risk of adverse liver-related events.
Key Distinction/Mechanism: Disease progression is driven by coordinated immune activity along the gut-liver axis, distinctively featuring IgA-expressing B-lineage cells localized in the portal regions of the liver.
Major Frameworks/Components:
- Spatial transcriptomics to map localized genetic expression in liver tissue.
- Cellular tissue analyses of IgA-expressing B-lineage cells.
- Evaluation of the gut-liver axis as a pathway for coordinated immune responses.
- Risk stratification models accounting for advanced liver fibrosis.
Branch of Science: Hepatology, Immunology, and Gastroenterology.
Future Application: Enables the development of highly specific risk stratification protocols, closer monitoring systems, and targeted immunotherapies that address gut-liver axis dysregulation in patients with metabolic liver diseases.
Why It Matters: Because MASLD progresses at different rates across patient populations, pinpointing this high-risk, IgA-enriched subtype allows clinicians to predict and manage severe liver-related events with greater precision, even when accounting for existing advanced fibrosis.
Researchers identified an IgA-enriched subgroup of MASLD associated with increased liver-related events. Spatial transcriptomics and tissue analyses further revealed IgA-expressing B-lineage cells in portal liver regions, highlighting coordinated immune activity along the gut–liver axis.
Study Reveals Coordinated Immune Activity in the Gut and Liver That May Help Explain Differences in Disease Progression
Metabolic dysfunction-associated steatotic liver disease can progress differently among patients. Researchers at Shinshu University identified an IgA-enriched MASLD subtype with an increased risk of liver-related events, even after accounting for advanced fibrosis. The team found increased IgA-associated immune activity in the gut and liver, including IgA-expressing B-lineage cells in portal regions. The findings highlight the gut–liver axis and suggest that IgA may help identify high-risk patients for closer monitoring and treatment research.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common liver condition that can follow vastly different trajectories among patients. Although fibrosis is a key indicator, some patients without advanced fibrosis can still develop serious liver-related events. This variation led researchers to investigate whether distinct clinical subtypes of MASLD could reveal additional clues about disease progression and risk.
Lecturer Takefumi Kimura, doctoral student Shun-ichi Wakabayashi, and Professor Naoki Tanaka from the Division of Gastroenterology at Shinshu University School of Medicine in Nagano, Japan, led the research team. The researchers analyzed clinical and laboratory information from 349 patients with biopsy-proven MASLD and used unsupervised clustering to identify groups with distinct characteristics. Four subgroups emerged. The team then used liver tissue analysis, single-cell RNA sequencing, spatial transcriptomics, and immunohistochemistry to examine the high-risk group. The study was published online in the Journal of Hepatology on July 15, 2026.
One subgroup, Cluster 2, stood out because patients exhibited higher blood levels of immunoglobulin A (IgA), an antibody involved in immune defense, along with older age, lower platelet counts, and more frequent diabetes. This group also demonstrated the highest prevalence of advanced fibrosis. During a median follow-up of 6.8 years, 20 liver-related events were recorded. The 5-year cumulative incidence of liver-related events in Cluster 2 was 24.0%. A blood IgA level of 318 mg/dL or higher independently predicted liver-related events, even after accounting for advanced fibrosis.
These findings were also observed in additional patient groups. In a separate cohort of 287 patients without liver biopsies, those who developed liver-related events had significantly higher blood IgA levels. An independent multicenter cohort of 272 patients reproduced the IgA-enriched subgroup and its association with liver-related events. In the original cohort, patients with both elevated IgA and advanced fibrosis had a 10-year cumulative incidence of liver-related events of 48%, compared with less than 5% in the remaining patients.
“These findings show that MASLD is not a single, uniform disease and that high IgA may help identify a subgroup with a distinct pattern of disease progression,” Dr. Kimura said. “The IgA-enriched phenotype provides another way to understand risk beyond fibrosis alone.”
The team next investigated why IgA might be associated with disease progression. In patients with MASLD and advanced fibrosis, IgA-positive cells increased in the intestinal mucosa and submucosa. Blood IgA levels were associated with EndoCAb IgG, a marker related to intestinal barrier dysfunction. In liver tissue, spatial transcriptomics showed higher IGHA1 expression in patients with advanced fibrosis, while immunohistochemistry revealed more IgA-positive cells in portal regions. Single-cell analysis showed that IGHA1 was primarily expressed by B-lineage cells, including plasma cells. Genes found alongside IGHA1 were linked to B-cell signaling and extracellular matrix organization, suggesting a connection between immune activity and liver remodeling.
“By examining both the intestine and liver, we found evidence of coordinated IgA-associated immune activity along the gut–liver axis,” Dr. Kimura said. “This provides a basis for further investigation of the biological features of the high-risk subgroup.”
Overall, the study identifies an IgA-enriched MASLD subtype associated with liver-related events beyond advanced fibrosis and highlights the complex relationship between the gut and liver. The findings could support future approaches that combine immune features with fibrosis measures to better classify MASLD. Further prospective studies and research in diverse populations will be necessary to determine how these findings could inform patient monitoring and future treatment research.
Published in journal: Journal of Hepatology
Title: IgA-enriched phenotype predicts liver-related events in MASLD
Authors: Takefumi Kimura, Shun-Ichi Wakabayashi, Takanobu Iwadare, Shohei Kondo, Taiki Okumura, Hiroyuki Kobayashi, Yuki Yamashita, Yuma Kamijo, Kaede Fujita, Tomoyuki Nakajima, Takuro Uchida, Tomoo Yamazaki, Mai Iwaya, Takeshi Uehara, Hidenori Toyoda, Takashi Kumada, Takeji Umemura, and Naoki Tanaka
Source/Credit: Shinshu University
Edited by: Scientific Frontline
Reference Number: med100926_02
